Finally, Valeant had some decent news and the stock is going off like a rocket

Valeant Pharmaceuticals has announced that its internal Ad-Hoc committee of board of directors — put together to dig through the troubled company’s accounting — has completed its work.

The ad-hoc committee says that it found no more issues with the company’s accounting beyond the $58 million misstatement that has forced it to delay its annual report.

The stock is up 17% in Tuesday’s pre-market trading session.

NOW WATCH: James Altucher makes an argument for not paying back your credit card debt

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at